BiotechTube

Osilodrostat

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Jan 16, 2023 → Oct 30, 2023

NCT ID
NCT05633953

About Osilodrostat

Osilodrostat is a pre-clinical stage product being developed by Recordati for Cushing's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05633953. Target conditions include Cushing's Syndrome.

What happened to similar drugs?

2 of 10 similar drugs in Cushing's Syndrome were approved

Approved (2) Terminated (1) Active (7)
🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
🔄Pasireotide sub-cutaneousNovartisPhase 3
🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3
🔄PasireotideNovartisPhase 3
✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
🔄mifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06430528Pre-clinicalRecruiting
NCT05633953Pre-clinicalCompleted
NCT05382156Pre-clinicalActive
NCT03606408Phase 2Completed

Competing Products

18 competing products in Cushing's Syndrome

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
40
Pasireotide sub-cutaneousNovartisPhase 3
40
osilodrostat + osilodrostat PlaceboNovartisPhase 3
40
OsilodrostatNovartisPhase 2
35
PasireotideNovartisPhase 3
40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
43
SOM230 s.c.NovartisPhase 2
35
Lu AG13909LundbeckPhase 2
39
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
40
osilodrostatRecordatiPhase 2
32
OsilodrostatRecordatiPre-clinical
27
mifepristoneCorcept TherapeuticsPhase 3
37
CORT125134Corcept TherapeuticsPhase 2
32
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
15
MifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
29